Masafumi Fukagawa

Masafumi Fukagawa's AcademicInfluence.com Rankings

Masafumi Fukagawa

Computer Science

#7027

World Rank

#7402

Historical Rank

Machine Learning

#2465

World Rank

#2497

Historical Rank

Artificial Intelligence

#2750

World Rank

#2793

Historical Rank

Database

#4089

World Rank

#4252

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Masafumi Fukagawa's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Masafumi Fukagawa Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Masafumi Fukagawa's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. (2017) (658)
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. (1993) (589)
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. (2004) (309)
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder (2013) (276)
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. (2010) (257)
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. (2013) (255)
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. (2015) (222)
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney DiseaseMineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update (2018) (213)
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. (2005) (199)
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. (2004) (173)
Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. (1994) (168)
Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. (2014) (167)
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. (2002) (164)
Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. (2007) (157)
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. (1998) (148)
Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. (2015) (146)
Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. (1989) (146)
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). (2008) (144)
FGF23-parathyroid interaction: implications in chronic kidney disease. (2010) (144)
Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. (1990) (143)
Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis Patients (2005) (142)
Role of oxidative stress in diabetic bone disorder. (2009) (141)
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. (2007) (133)
Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. (2007) (131)
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. (2005) (129)
Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. (2012) (129)
Regulation of parathyroid hormone synthesis in chronic renal failure in rats. (1991) (128)
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. (2011) (128)
Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism (2005) (125)
Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. (2009) (123)
Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients (2013) (122)
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. (2004) (119)
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. (2010) (117)
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. (2009) (115)
Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease (2009) (107)
Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. (1994) (106)
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. (2014) (102)
Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1 (2016) (100)
Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. (2006) (100)
Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction (2017) (92)
Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. (1997) (88)
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR) (2012) (85)
Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. (1995) (83)
The role of FGF23 in CKD—with or without Klotho (2012) (82)
Phosphate-a poison for humans? (2016) (81)
Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. (2011) (80)
Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction (2018) (78)
Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. (2008) (74)
Role of Oxidative Stress and Indoxyl Sulfate in Progression of Cardiovascular Disease in Chronic Kidney Disease (2011) (72)
Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. (2005) (72)
Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. (2006) (71)
In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. (2003) (71)
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. (2019) (70)
Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. (2006) (70)
Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. (1999) (70)
Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. (2009) (69)
A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. (2014) (68)
Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. (2014) (67)
Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients (2011) (67)
p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. (2013) (66)
With or without the kidney: the role of FGF23 in CKD. (2005) (65)
Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. (2003) (65)
The essence of treatment for CKD patients (2009) (63)
Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. (2012) (59)
Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018 (2018) (59)
22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy. (2013) (59)
p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress (2014) (57)
Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. (2013) (56)
Uremic osteoporosis (2013) (56)
Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. (2014) (56)
Altered expression of aquaporins 1 and 4 coincides with neurodegenerative events in retinas of spontaneously diabetic Torii rats. (2010) (55)
Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. (1998) (53)
Role of fibroblast growth factor 23 in health and in chronic kidney disease (2005) (52)
Diseases of the parathyroid gland in chronic kidney disease (2011) (52)
Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial (2018) (52)
Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. (2004) (51)
Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. (2013) (50)
Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. (2014) (50)
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. (2018) (48)
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients (2017) (47)
[Renal osteodystrophy and secondary hyperparathyroidism]. (2002) (47)
Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy (2004) (47)
Medical and surgical aspects of parathyroidectomy. (1999) (46)
Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients (2018) (46)
Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. (2014) (46)
Oxidative and Nitrosative Stress and Progression of Diabetic Nephropathy in Type 2 Diabetes (2010) (46)
Direct injections of calcitriol into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction (1995) (45)
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. (2013) (44)
Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. (2007) (43)
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. (2012) (43)
A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. (2013) (43)
Insufficiency of PTH action on bone in uremia. (2006) (43)
Management of secondary hyperparathyroidism: how and why? (2017) (43)
Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. (2016) (42)
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. (2017) (42)
PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism (2016) (42)
New insights into the role of fibroblast growth factor 23 in chronic kidney disease. (2010) (42)
Recent progress in management of secondary hyperparathyroidism of chronic renal failure. (1993) (41)
Uremic Toxicity and Bone in CKD (2017) (41)
The kidney and bone metabolism: Nephrologists' point of view (2006) (40)
Role of Cyclase Activating Parathyroid Hormone (1-84 PTH) Measurements During Parathyroid Surgery: Potential Improvement of Intraoperative PTH Assay (2002) (40)
Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury (2015) (40)
Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients--the Japanese strategy. Japanese Working Group on PEIT of Parathyroid, Tokyo, Japan. (1999) (39)
Altered material properties are responsible for bone fragility in rats with chronic kidney injury. (2015) (39)
Uremic Toxins and Oral Adsorbents (2011) (39)
Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients (2015) (39)
A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro (2018) (39)
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. (2015) (37)
Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid gland in humans. (2003) (37)
Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. (2002) (37)
Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D (2011) (37)
Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. (2001) (37)
22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. (1999) (36)
A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy. (2007) (36)
Cell biology of parathyroid hyperplasia in uremia. (1999) (36)
Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. (2019) (36)
Chronic kidney disease and bone metabolism (2015) (36)
Calcium Homeostasis and Imbalance (2002) (35)
Comparison between Whole and Intact Parathyroid Hormone Assays (2011) (35)
Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine (2021) (35)
Maintenance of trabecular structure and bone volume by vitamin K2 in mature rats with long-term tail suspension (2002) (35)
Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. (2006) (34)
Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects (1997) (34)
Vitamin D Receptor Activator Reduces Oxidative Stress in Hemodialysis Patients With Secondary Hyperparathyroidism (2011) (34)
The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. (2011) (34)
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. (2012) (34)
Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. (2002) (34)
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. (2012) (33)
2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report (2019) (33)
Prevalence and Cardiovascular Features of Japanese Hemodialysis Patients with Fabry Disease (2009) (31)
Anti-Oxidative Effect of Vitamin D Analog on Incipient Vascular Lesion in Non-Obese Type 2 Diabetic Rats (2013) (31)
Effects of AST-120 on Left Ventricular Mass in Predialysis Patients (2011) (31)
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. (2008) (30)
Is aplastic osteodystrophy a disease of malnutrition? (2000) (30)
Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements. (2009) (30)
Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study (2017) (29)
A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. (2019) (29)
Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. (2017) (29)
Resistance of parathyroid cell to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure. (1995) (29)
Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention (2008) (29)
Source matters: from phosphorus load to bioavailability. (2011) (29)
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. (2005) (28)
A 10-year retrospective cohort study on the risk factors for peritoneal dialysis-related peritonitis: a single-center study at Tokai University Hospital (2014) (28)
Nephrology in earthquakes: sharing experiences and information. (2007) (28)
Sequential Changes in Plasma Intact and Whole Parathyroid Hormone Levels during Parathyroidectomy for Secondary Hyperparathyroidism (2005) (28)
Clinical Characteristics and Cardiovascular Outcomes of Hemodialysis Patients with Atrial Fibrillation: A Prospective Follow-Up Study (2011) (28)
Natural History of Mineral and Bone Disorders After Living‐Donor Kidney Transplantation: A One‐Year Prospective Observational Study (2011) (28)
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. (2011) (27)
Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. (2007) (27)
Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. (2002) (27)
Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. (2007) (27)
Prevalence of chronic kidney disease in Asia: a systematic review and analysis (2022) (27)
FGF23: a key player in mineral and bone disorder in CKD. (2009) (27)
Study of Plasma Exchange for Liver Failure: Beneficial and Harmful Effects (2004) (26)
Is hepcidin the star player in iron metabolism in chronic kidney disease? (2009) (26)
Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. (2011) (26)
Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. (1996) (26)
Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. (2005) (26)
Cost‐effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan (2013) (26)
Effectiveness of β2-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study (2011) (26)
Development of bioartificial renal tubule devices with lifespan-extended human renal proximal tubular epithelial cells. (2011) (25)
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study (2016) (25)
FGF23: its role in renal bone disease (2006) (25)
Circulating osteoprotegerin is not removed through haemodialysis membrane. (2002) (24)
[A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcemic action]. (2002) (24)
Association Between Indoxyl Sulfate and Skeletal Resistance in Hemodialysis Patients (2010) (24)
Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury. (2019) (24)
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. (2021) (24)
Uremic toxin and bone metabolism (2005) (24)
Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats (1997) (24)
Heme-Oxygenase Upregulation Ameliorates Angiotensin II-Induced Tubulointerstitial Injury and Salt-Sensitive Hypertension (2007) (23)
Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride (2011) (23)
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS (2020) (23)
Exercise Therapy for Management of Type 2 Diabetes Mellitus: Superior Efficacy of Activity Monitors over Pedometers (2016) (23)
Upregulation of α3β1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy (2016) (23)
Chronic progressive interstitial fibrosis in renal disease--are there novel pharmacological approaches? (1999) (23)
Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate (2018) (23)
Evaluation of bioartificial renal tubule device prepared with lifespan-extended human renal proximal tubular epithelial cells. (2012) (22)
Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients: Rationale and Study Design (2011) (22)
Role of Circulating Fibroblast Growth Factor 23 in the Development of Secondary Hyperparathyroidism (2005) (22)
Effects of Raloxifene on Bone Mineral Metabolism in Postmenopausal Japanese Women on Hemodialysis (2011) (22)
Coronary Plaque Morphology Using Virtual Histology–Intravascular Ultrasound Analysis in Hemodialysis Patients (2011) (22)
The Negative Ca2+ Balance Is Involved in the Stimulation of PTH Secretion (2002) (22)
Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism (2018) (22)
Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study (2019) (21)
Etelcalcetide for the treatment of secondary hyperparathyroidism (2017) (21)
Resistance of the parathyroid glands to vitamin D in renal failure: implications for medical management. (1997) (21)
Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism (2008) (21)
Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2022) (20)
Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia (2003) (20)
Parathyroid hormone contributes to the down‐regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF‐&kgr;B signaling pathway in secondary hyperparathyroidism (2017) (20)
Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study (2015) (20)
Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. (2017) (20)
Combination use of vitamin K2 further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension rats (2003) (20)
Impact of Cinacalcet Hydrochloride on the Achievement of the Japanese Society for Dialysis Therapy (JSDT) Guideline Targets: A post‐hoc Analysis of the KRN1493 Study (2008) (19)
The making of a bone in blood vessels: from the soft shell to the hard bone. (2007) (19)
Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric Dimethylarginine Levels and Oxidative Stress in Normotensive Patients with Chronic Kidney Disease (2014) (19)
Characterization and quantification of proliferating cell patterns in endocapillary proliferation. (2012) (18)
The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions (2010) (18)
Regression of parathyroid hyperplasia by calcimimetics--fact or illusion? (2008) (18)
Critical issues of PTH assays in CKD. (2009) (18)
Cinacalcet Induces Apoptosis in Parathyroid Cells in Patients with Secondary Hyperparathyroidism: Histological and Cytological Analyses (2014) (18)
JTT-751 for Treatment of Patients with Hyperphosphatemia on Peritoneal Dialysis (2014) (18)
Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism. (2003) (17)
Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder. (2012) (17)
Fetuin-mineral complex: a new potential biomarker for vascular calcification? (2009) (17)
Serum Pro‐hepcidin as an Indicator of Iron Status in Dialysis Patients (2008) (17)
Extensive deep vein thrombosis in a postpartum woman with Behçet's disease associated with nephrotic syndrome. (2007) (16)
Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. (2008) (16)
Regulation of parathyroid function in chronic kidney disease (CKD) (2006) (16)
Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan (2013) (16)
Human transmissible spongiform encephalopathies. (1998) (16)
Decline in the Functional Status and Mortality in Patients on Hemodialysis: Results from the Japan Dialysis Outcome and Practice Patterns Study. (2019) (16)
The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus (2015) (16)
Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner. (2019) (16)
Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in parathyroid hyperplasia in chronic dialysis patients (1997) (16)
Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study (2020) (15)
A Prospective Multicenter Randomized Controlled Study on Interleukin‐6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study (2016) (15)
Treatment With Pravastatin Attenuates Oxidative Stress and Protects Osteoblast Cell Viability From Indoxyl Sulfate (2011) (15)
Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities (2015) (15)
Low-calcium dialysate improves mineral metabolism in hemodialysis patients. (2007) (15)
Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS) (2018) (15)
Carvedilol Ameliorates Low-Turnover Bone Disease in Non-Obese Type 2 Diabetes (2011) (15)
Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy (2013) (15)
Resurgence of parathyroidectomy: evidence and outcomes (2017) (15)
Relationship Between the Weight of Parathyroid Glands and Their Secretion of Parathyroid Hormone in Hemodialysis Patients With Secondary Hyperparathyroidism (2008) (15)
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis (2019) (15)
Role of parathyroid intervention in the management of secondary hyperparathyroidism. (2003) (15)
Efficacy of Percutaneous Ethanol Injection Therapy for Secondary Hyperparathyroidism in Patients on Hemodialysis as Evaluated by Parathyroid Hormone Levels According to K/DOQI Guidelines (2005) (14)
Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study (2018) (14)
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. (2008) (14)
Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism (2019) (14)
The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study (2017) (14)
Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges (2010) (14)
Pathogenesis and medical treatment of secondary hyperparathyroidism. (1997) (14)
Combination Therapy of Intravenous Maxacalcitol and Percutaneous Ethanol Injection Therapy Lowers Serum Parathyroid Hormone Level and Calcium × Phosphorus Product in Secondary Hyperparathyroidism (2005) (14)
Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial (2014) (14)
Secondary Hyperparathyroidism and Protein‐Energy Wasting in End‐Stage Renal Disease (2018) (14)
A Japanese approach for CKD-MBD (2013) (14)
Ectopic Calcification as Abnormal Biomineralization (2006) (14)
Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. (2003) (14)
IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. (2003) (13)
Association of Serum Bicarbonate with Bone Fractures in Hemodialysis Patients: The Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D) (2014) (13)
Advanced oxidation protein products contribute to chronic kidney disease‐induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway (2021) (13)
Global Dialysis Perspective: Japan. (2020) (13)
Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study (2020) (13)
Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride. (2010) (13)
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients (2018) (13)
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease (2017) (13)
Magnesium as a new player in CKD: too little is as bad as too much? (2017) (13)
Indoxyl Sulfate Contributes to Adipose Tissue Inflammation through the Activation of NADPH Oxidase (2020) (13)
The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy. (2016) (13)
Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. (2018) (13)
Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study (2018) (13)
Attenuated up‐regulation of vitamin D‐dependent calcium‐binding proteins by 22‐oxa‐1,25‐dihydroxyvitamin D3 in uremic rats: A possible mechanism for less‐calcemic action (1998) (13)
A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients . (2017) (12)
Clinical Implications of Assessing Coronary Flow Velocity Reserve and Plasma Endothelin-1 in Hypertensive Patients (2005) (12)
An Efficacy of Intensive Vitamin D Delivery to Neointimal Hyperplasia in Recurrent Vascular Access Stenosis (2016) (12)
The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. (2013) (12)
Present status of renal replacement therapy in Asian countries as of 2016: Cambodia, Laos, Mongolia, Bhutan, and Indonesia (2019) (12)
Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan (2018) (12)
Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism (2015) (12)
Frontiers in parathyroid physiology (2006) (12)
Design and baseline characteristics of the LANDMARK study (2016) (12)
Menatetrenone rescues bone loss by improving osteoblast dysfunction in rats immobilized by sciatic neurectomy. (2005) (12)
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate (2017) (12)
Carbon Monoxide Rescues the Developmental Lethality of Experimental Rat Models of Rhabdomyolysis-Induced Acute Kidney Injury (2020) (12)
TGF-Beta Signaling in Bone with Chronic Kidney Disease (2018) (12)
Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification? (2012) (12)
Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders (2018) (12)
Parathyroidectomy Markedly Reduces Oxidative Stress in a Patient with Primary Hyperparathyroidism (2011) (12)
A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. (2002) (12)
Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future? (2010) (12)
The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism (2008) (11)
A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism (2017) (11)
Putative Role of Endothelial Lipase in Dialysis Patients with Hypoalbuminemia and Inflammation (2008) (11)
Case of peritoneal dialysis-related acute hydrothorax, which was successfully treated by thoracoscopic surgery, using collagen fleece. (2011) (11)
Autophagy: a two-edged sword in diabetes mellitus. (2013) (11)
Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. (1995) (11)
Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review (2008) (11)
Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease (2012) (11)
Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients (2019) (11)
Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder (2013) (11)
Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. (2012) (11)
Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy (2014) (10)
Relationship between Biochemical Markers and Radial Cortical Bone Changes in Hemodialysis Patients (2011) (10)
Controversy about COOPERATE ABPM Trial Data (2006) (10)
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation (2020) (10)
Skeletal resistance to parathyroid hormone as a background abnormality in uremia (2003) (10)
Menatetrenone ameliorates reduction in bone mineral density and bone strength in sciatic neurectomized rats. (2003) (10)
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. (2017) (10)
[The pleiotropic effects of vitamin D on kidney disease]. (2007) (10)
Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases (2008) (10)
1,25‐dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine (2009) (10)
Ultrasonographic evaluation of parathyroid hyperplasia. (1997) (9)
Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. (2010) (9)
Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway (2021) (9)
Bio‐Intact Parathyroid Hormone and Intact Parathyroid Hormone in Hemodialysis Patients With Secondary Hyperparathyroidism Receiving Intravenous Calcitriol Therapy (2004) (9)
Chronic Kidney Disease-Mineral and Bone Disorder in Asia (2017) (9)
Cinacalcet and Clinical Outcomes in Dialysis (2015) (9)
Modulation of parathyroid cell function by calcium ion in health and uremia. (1999) (9)
Ever-changing concepts of calciphylaxis. (2004) (9)
[Chronic kidney disease-mineral and bone disorder (CKD-MBD)]. (2006) (9)
Circulating Osteoprotegerin Affects Bone Metabolism in Dialysis Patients With Mild Secondary Hyperparathyroidism (2006) (9)
Evaluation of bioartificial renal tubule device prepared with human renal proximal tubular epithelial cells cultured in serum-free medium (2013) (8)
Predicting the risk of acute kidney injury in earthquake victims (2009) (8)
Cerebral venous thrombosis in adult nephrotic syndrome due to systemic amyloidosis. (2006) (8)
Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level (2019) (8)
New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients (2008) (8)
Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties (2020) (8)
Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study. (2016) (8)
Adrenal Venous Sampling Is Useful for a Definitive Diagnosis in Cushing's Syndrome with Bilateral Adrenal Tumors. (2016) (8)
Old and New Drugs for the Management of Bone Disorders in CKD (2021) (8)
Calcium abnormalities of dialysis patients (2005) (8)
Adipocytes do not significantly contribute to plasma angiotensinogen (2016) (8)
Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy (2016) (8)
Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation (2019) (8)
Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans (2018) (8)
Assessment of the accuracy of an intermittent‐scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study (2021) (7)
Towards Cost‐effective Strategies for Treatment of Chronic Kidney Disease‐Mineral and Bone Disorder in Japan (2009) (7)
Overexpression of thioredoxin 1 in transgenic mice suppresses development of diabetic nephropathy (2007) (7)
Policy for developing clinical practice guidelines of Japanese Society for Dialysis Therapy (2017) (7)
Extracorporeal Albumin Dialysis (2004) (7)
Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report. (2018) (7)
Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. (2005) (7)
Pasteurella multocida peritonitis associated with a cat in a peritoneal dialysis patient using an automated cycler device (2012) (7)
Uremic bone disease: advances over the last 30 years. (1999) (7)
Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. (2014) (7)
En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient (2017) (7)
Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients (2021) (7)
Whole or fragmentary information on parathyroid hormone? (2007) (6)
Two cases of nephrotic syndrome (NS)-induced acute kidney injury (AKI) associated with renal hypouricemia. (2011) (6)
Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS (2021) (6)
Direct Injection of Calcitriol or Its Analog Improves Abnormal Gene Expression in the Hyperplastic Parathyroid Gland in Uremia (2007) (6)
Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes. (2012) (6)
Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients (2017) (6)
[A case of mitochondrial encephalomyopathy with nephrotic syndrome]. (1986) (6)
A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein (2020) (6)
An introduction to CKD-MBD research: restart for the future (2017) (6)
A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats. (2002) (6)
Role of Uremic Toxins and Oxidative Stress in Chronic Kidney Disease (2011) (6)
In and out of the bone: can the osteocyte escape skeletal jail and yet regulate mineralization? (2014) (6)
A case of the watery diarrhea-hypokalemia-achlorhydria syndrome: successful preoperative treatment of watery diarrhea with a somatostatin analogue. (1989) (6)
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor (2017) (6)
Parathyroidectomy or Calcimimetic to Treat Hypercalcemia after Kidney Transplantation? (2016) (6)
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy (2020) (5)
High serum estradiol concentrations in postmenopausal women with end-stage renal disease. (2005) (5)
Renal failure and hyperparathyroidism. (1997) (5)
Renal Function and Bisphosphonate Safety (2007) (5)
Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease (2020) (5)
Marked increase in bone formation markers after cinacalcet treatment by mechanisms distinct from hungry bone syndrome in a haemodialysis patient (2009) (5)
Tako-tsubo cardiomyopathy associated with brain metastasis of seminoma in a patient with chronic kidney disease. (2007) (5)
Pseudo-azotaemia due to intraperitoneal urine leakage: a report of two cases (2010) (5)
Measurements of blood DMSO and DMSO2 in a healthy person and a hemodialysis patient (2001) (5)
Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes (2021) (5)
Management of Mineral and Bone Disorder in Chronic Kidney Disease: Quo Vadis? (2009) (5)
Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. (2020) (5)
Shared decision making for the initiation and continuation of dialysis: a proposal from the Japanese Society for Dialysis Therapy (2021) (5)
Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients (2019) (5)
Novel Electrochemiluminescence Immunoassay Exclusively for Full‐length Parathyroid Hormone during Treatment with Cinacalcet for Secondary Hyperparathyroidism (2011) (5)
Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis. (2020) (5)
Jury still out on whether FGF23 is a direct contributor, a useful biomarker, or neither. (2021) (5)
[Mechanism of secondary hyperparathyroidism]. (2002) (5)
A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy (2019) (5)
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide (2017) (5)
The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels (2018) (5)
Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients (2017) (4)
Magnesium as a Janus-faced inhibitor of calcification. (2020) (4)
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Gene therapy for secondary hyperparathyroidism]. (2010) (4)
Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism (2020) (4)
Proposal of daignostic criteria for calciphylaxis based on nationwide surveillance in Japan (2012) (4)
Kidney transplantation restored uncoupled bone turnover in end-stage renal disease. (2012) (4)
Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD) (2013) (4)
Present status of renal replacement therapy in Asian countries as of 2017: Vietnam, Myanmar, and Cambodia (2020) (4)
Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America (2020) (4)
Advanced Oxidation Protein Products Contribute to Renal Tubulopathy via Perturbation of Renal Fatty Acids. (2020) (4)
Contrast-induced ultrasonography with Levovist in a case of exercise-induced acute kidney injury without rhabdomyolysis. (2010) (4)
A Retrospectively Diagnosed Case of IgG4-Related Tubulointerstitial Nephritis Showing Good Renal Outcome and Pathological Progress (2013) (4)
[hypocalcemia and hypercalcemia]. (2006) (4)
Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism (2019) (4)
Control of Parathyroid Function in Patients with a Short History of Hemodialysis (2005) (4)
[Role of the kidney in mineral metabolism]. (2007) (4)
Recombinant Long-Acting Thioredoxin Ameliorates AKI to CKD Transition via Modulating Renal Oxidative Stress and Inflammation (2021) (4)
A rare case of Cushing's syndrome due to bilateral adrenocortical adenomas. (2014) (4)
Kidney Diseases Enhance Expression of Tetraspanin-8: A Possible Protective Effect against Tubular Injury (2014) (4)
An acute phase protein α1-acid glycoprotein mitigates AKI and its progression to CKD through its anti-inflammatory action (2021) (4)
Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study (2020) (4)
Parathyroidectomy versus cinacalcet among patients undergoing hemodialysis. (2022) (3)
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis (2020) (3)
Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer? (2007) (3)
Is lanthanum carbonate safer and more effective than calcium carbonate for hyperphosphatemia in dialysis patients? (2005) (3)
International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study (2019) (3)
Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study (2019) (3)
Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure. (1995) (3)
[Case of goodpasture syndrome associated with minimal change nephrotic syndrome (MCNS) in a patient with rheumatoid arthritis (RA)]. (2009) (3)
CHAPTER 103 – Renal Failure and Secondary Hyperparathyroidism (2005) (3)
Adenovirus-mediated functional gene transfer into parathyroid cells in vivo and in vitro. (2003) (3)
Results of the survey on practice patterns including MBD management at dialysis facilities (2011) (3)
Overt intracardiac shunt flow after arteriovenous graft placement (2013) (3)
[Basic and clinical aspects of calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation]. (2008) (3)
Development of a Technique for Introduction of an Expressed cDNA into Parathyroid Cells by Direct Injection (2010) (3)
Behavior Modification Maintenance with Long-Term Blood Glucose and Weight Management in Prader–Willi Syndrome Complicated with Diabetes: Team Management Approach Combined with Pharmacological Treatment (2019) (3)
Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR) (2021) (3)
Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine. (2013) (3)
Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism (2019) (3)
How to Apply and Adapt International Guidelines on Bone Metabolism and Disease to the Management of Japanese Dialysis Patients (2005) (3)
Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? (2007) (3)
Interrelationships between sclerostin, secondary hyperparathyroidism, and bone metabolism in patients on hemodialysis. (2021) (3)
[Chronic kidney disease (CKD) and bone. The mechanisms of chronic kidney disease--mineral and bone disorder (CKD-MBD)]. (2009) (3)
Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT—a single-centre trial (2008) (3)
[Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.] (2017) (3)
Feasibility of photodynamic therapy for secondary hyperparathyroidism in chronic renal failure rats (2017) (3)
Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study. (2021) (3)
Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats (2017) (3)
Fibroblast Growth Factor 23 and Phosphate Homeostasis (2005) (3)
22-Oxacalcitriol attenuates bone loss in nonobese type 2 diabetes. (2015) (3)
Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment (2018) (2)
[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. (2010) (2)
Effect of Scavenging Circulating Reactive Carbonyls by Oral Pyridoxamine in Uremic Rats on Peritoneal Dialysis (2016) (2)
[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. (2007) (2)
Epidemiology and outcome - 1 (2009) (2)
Falsely Elevated Serum Creatinine Associated With IgM Paraproteinemia (2019) (2)
Cardiovascular disease history and β-blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies (2021) (2)
[Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism]. (2011) (2)
Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring. (2018) (2)
MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III STUDY (2016) (2)
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)]. (2015) (2)
Variant of lymphocytic infundibulo-neurohypophysitis presenting with unique clinical and radiological features. (2012) (2)
The estimation of bicarbonate concentration in hemodialysis patients from blood biochemical values (2010) (2)
Amino-terminal form of parathyroid hormone in CKD. (2010) (2)
Another role for nephrologists in disaster medicine (2013) (2)
Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients (2021) (2)
[Current Topics on Vitamin D. Vitamin D and chronic kidney disease]. (2015) (2)
[Role of vitamin D in the pathogenesis of renal osteodystrophy]. (2004) (2)
Post-kidney transplant soluble Klotho levels are determined by pretransplant soluble Klotho levels in both living donors and recipients (2021) (2)
A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients (2018) (2)
A Rare Case of Subclinical Primary Aldosteronism and Subclinical Cushing's Syndrome without Cardiovascular Complications. (2016) (2)
Introduction to renal osteodystrophy: calcium metabolism in health and uremia. (1999) (2)
Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism (2020) (2)
Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism? (2006) (2)
Development of a technique for introduction of an expressed complementary deoxyribonucleic acid into parathyroid cells by direct injection. (2010) (2)
[PTH and bone metabolism in chronic dialysis patients]. (2001) (2)
Diabetes - experimental models (2013) (2)
Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-. (2017) (2)
Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial (2021) (2)
A Case of a TSH-secreting Pituitary Adenoma Associated with Evans' Syndrome. (2015) (2)
Excess risk of cardiovascular events in patients in the United States vs. Japan with chronic kidney disease is mediated mainly by left ventricular structure and function. (2023) (2)
Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study (2019) (1)
[Functional disorder of the parathyroid gland and vascular calcification in hemodialysis patients]. (2005) (1)
α1-Acid Glycoprotein Attenuates Adriamycin-Induced Nephropathy via CD163 Expressing Macrophage Induction. (2020) (1)
P1404A PHASE 2 OPEN-LABEL, SINGLE-ARM, FIRST JAPANESE STUDY OF TENAPANOR, A NOVEL PHOSPHATE ABSORPTION INHIBITOR, FOCUSING ON PILL BURDEN DECREASE IN PATIENTS WITH HYPERPHOSPHATEMIA UNDERGOING HEMODIALYSIS (2020) (1)
Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model (2019) (1)
Clinical features of dialysis patients with atrial fibrillation (2007) (1)
[Hormonal regulation of phosphate balance]. (2012) (1)
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. (2016) (1)
First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants (2022) (1)
New insight into the pathogenesis of secondary hyperparathyroidism in chronic renal failure (1991) (1)
Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study (2022) (1)
SO032REGIONAL VARIATION IN MINERAL AND BONE DISORDER (MBD) MARKERS AND TREATMENT AT DIALYSIS START: RESULTS FROM THE DOPPS (2017) (1)
[Adynamic bone disease]. (2004) (1)
Dialysis: Effect of cinacalcet on survival—the saga continues (2013) (1)
Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients. (2016) (1)
Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports (2022) (1)
[Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease]. (2009) (1)
MP368A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE): A MULTICENTER, SINGLE AND MULTIPLE DOSE STUDY IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM (2016) (1)
5. Familial Hypocalciuric Hypercalcemia (2007) (1)
Imaging and intervention of parathyroid hyperplasia (2010) (1)
Corrigendum to “A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy” (2020) (1)
Equivalent continuous clearances EKR and stdK in incremental haemodialysis (2012) (1)
Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study (2021) (1)
Glycemic Control After Kidney Transplantation Using Sensor-augmented Insulin Pump Therapy in a Patient with Slowly Progressive Type 1 Diabetes Mellitus. (2020) (1)
[Fibroblast growth factor (FGF)-23 in patients with hypoparathyroidism]. (2005) (1)
Development of evocalcet for unmet needs among calcimimetic agents (2020) (1)
Evaluation of adrenal function in Cushing's syndrome model rats (2018) (1)
Cyclosporine A nephrotoxicity in patients with Behçet's disease. (1986) (1)
PREVALENT HAEMODIALYSIS PATIENTS (2013) (1)
[Bone and bone related biochemical examinations. Hormone and hormone related substances. Parathyroid hormone]. (2006) (1)
Medical management after parathyroid intervention (2008) (1)
A Survey on the Current Status of Ophthalmological Consultations in Patients With Diabetes Undergoing Maintenance Hemodialysis and the Effectiveness of Education on Consultation Behavior –Experience of a Single Hemodialysis Clinic in Japan (2022) (1)
Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study” (2019) (1)
No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism. (2006) (1)
Role of osteoclastic dysfunction in the development of renal bone disease. (2003) (1)
Semiquantitative analysis of virtual histology derived from intravascular ultrasound images at vascular access stenosis (2019) (1)
[Update on recent progress in vitamin D research. The role of vitamin D in management of CKD-MBD.] (2017) (1)
[Relationship between lipid and glucose metabolism and bone mineral metabolism : pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia]. (2008) (1)
[An electron microscopic study of the glomerular epithelial detachment]. (1985) (1)
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia (2021) (1)
[Pathogenesis and clinical condition of hyperphosphatemic diseases]. (2016) (1)
Very high incidence and relatively mild clinical symptoms of dialysis population with hypoparathyroidism (1996) (1)
Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention (2008) (1)
Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study (2017) (1)
Focal and segmental glomerular sclerosis observed in preeclamptic nephropathy. (1987) (1)
Course of Hyperkalemia in Patients on Hemodialysis (2022) (0)
Progression & risk factors CKD 1-5 (1) (2011) (0)
Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study (2017) (0)
[Effects of reduced dialysate calcium on mineral metabolism in hemodialysis patients]. (2005) (0)
Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial (2022) (0)
[Bone mineral metabolism that kidney controls]. (2013) (0)
MP348ADDITION OF SEVELAMER AND MORTALITY: THE WORLDWIDE DOPPS STUDY (2016) (0)
CKD BONE DISEASE (2014) (0)
Determination of parathyroid hormone levels in fine needle aspirates of ectopic parathyroid glands. (2002) (0)
Glycemic load is associated with oxidative stress among prevalent maintenance hemodialysis patients (2014) (0)
Subject Index Vol. 28, 2008 (2008) (0)
MO054INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM AMELIORATES BONE FRAGILITY THROUGH IMPROVED FUNCTION AND DECREASED APOPTOSIS OF OSTEOCYTE THROUGH BLOCKING OSTEOCYTIC ACTION (2017) (0)
Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients (2023) (0)
P1455PRIORITIZATION BY MEDICAL DIRECTORS OF NUTRITIONAL PROTEIN VERSUS DIETARY PHOSPHORUS CONTROL IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH MORTALITY IN THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS) (2020) (0)
Regulation of Renin Expression by Β1-Integrin in As4.1 Juxtaglomerular Line Cells (2023) (0)
Contents Vol. 124, 2013 (2014) (0)
The Parathyroid Gland (2002) (0)
[Chronic renal failure]. (2005) (0)
Glomeruloid haemangiomas associated with generalized oedema in a patient with atypical POEMS syndrome (2010) (0)
Continuous Glucose Monitoring Effects on Blood Glucose Management in Diabetic Patients on Hemodialysis-Results in the Patients from Single Hospital (2017) (0)
Bone disease in CKD 1-5 (2011) (0)
Subject Index Vol. 26, 2006 (2007) (0)
Effect of Glucocorticoid receptor antagonist administration in a Cushing's syndrome model rat (2019) (0)
Reprint of “Critical issues of PTH assays in CKD” [Bone 44 (2009) 666–670] (2009) (0)
Renin Production and Involvement of ß1 Integrin in Blood Pressure Regulation in Diabetic Nephropathy (2018) (0)
[Molecular biology in regulation of kidney functions: Vitamin D3]. (2006) (0)
Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan (2020) (0)
DIALYSIS MINERAL BONE DISEASE (2014) (0)
Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width (2022) (0)
Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study (2022) (0)
Factors associated with calcification of the thoracic aorta determined by three-dimensional computed tomography (2010) (0)
Parathyroid gland mass reduction by ethanol injection is an effective adjunct to calcitriol pulse therapy in severe hyperparathyroidism of chronic dialysis patients (1992) (0)
Original Full Length Article 22-Oxacalcitriol attenuates bone loss in nonobese type 2 diabetes (2015) (0)
Serum Sclerostin Levels and Mortality in Hemodialysis Patients: An 8-Year Prospective Study (2022) (0)
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism (2022) (0)
Consultants for the American Journal of Nephrology 2009 (2009) (0)
Supplementary Material for: Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D (2017) (0)
Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism (2020) (0)
List of Reviewers 2016–2017 (2017) (0)
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE (2022) (0)
[Nephropathies associated with rheumatoid arthritis. Abnormalities in urinalysis and renal function and their pathogenesis]. (1988) (0)
[Experimental and clinical studies of a prostaglandin F2-alpha main urinary metabolite (MUM) radioimmunoassay kit]. (1978) (0)
Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study (2019) (0)
LIST OF REVIEWERS 2017–2018 (2018) (0)
Kobe University Repository : Kernel タイトル Tit le Marked increase in bone format ion markers after cinacalcet t reatment by mechanisms dist inct from hungry bone syndrome in a haemodialysis (2018) (0)
The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) – Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes (2022) (0)
[Disturbance of phosphorus metabolism in chronic kidney disease]. (2009) (0)
DIALYSIS MINERAL BONE DISEASE MO043 ADDITION OF SEVELAMER HYDROCHLORIDE ASSOCIATES WITH IMPROVED SURVIVALON HEMODIALYSIS: THE JAPAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (J-DOPPS) (2014) (0)
PJ-657 Asymmetric Dimethylarginine (ADMA) is an Incipient Marker of Arteriosclerosis in Kidney and Heart(Kidney/Renal circulation-5, The 71st Annual Scientific Meeting of the Japanese Circulation Society) (2007) (0)
Mineral and bone disease - CKD 1-5 (2012) (0)
Corrigendum to “Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients,” [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020] (2021) (0)
[Progress in diagnosis and therapy: familial hypocalciuric hypercalcemia]. (2007) (0)
Response to Letter to the Editor From Sumi et al: “Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients Receiving Hemodialysis” (2022) (0)
Investigation of atrophic adrenal glands in Cushing's syndrome model rats induced by the administration of dexamethasone (2017) (0)
Consultants for the American Journal of Nephrology 2008 (2008) (0)
[Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients]. (2007) (0)
[Role of OPG in calcium metabolism]. (2002) (0)
[Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action]. (2008) (0)
Emerging Roles of Cinacalcet Hydrochloride in the Management of CKD‐MBD (2009) (0)
Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center. (2022) (0)
FP295Acute kidney injury promotes osteoid formation in rats (2019) (0)
Old and New Drugs for the Management of Bone Disorders in CKD (2021) (0)
Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis—A post hoc analysis of the LANDMARK study (2022) (0)
Bone and mineral metabolism in end-stage kidney disease (2016) (0)
[Clinical application of calcimimetics]. (2004) (0)
SP617INDOXYL SULFATE AND MORTALITY IN HAEMODIALYSIS PATIENTS: RESULTS FROM THE JAPAN DIALYSIS OUTCOMESAND PRACTICE PATTERNS STUDY (J-DOPPS) (2018) (0)
[Physiopathology and therapy of renal osteodystrophy and secondary hyperparathyroidism]. (1999) (0)
Title Page. Formal Assessment of Donor Kidney Function Should Be Mandatory (2011) (0)
Fibroblast growth factor 23‐Klotho and mineral metabolism in the first year after pediatric kidney transplantation: A single‐center prospective study (2022) (0)
Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus (2017) (0)
A case of TSH secreting pituitary adenoma with Evans' syndrome (2015) (0)
New Roles of Parathyroid Hormone (2018) (0)
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism (2022) (0)
List of reviewers 2015–2016 (2016) (0)
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis (2019) (0)
MO547ASSOCIATION BETWEEN SERUM INDICES OF IRON METABOLISM AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH PREDIALYSIS CHRONIC KIDNEY DISEASE (2021) (0)
Cinacalcet : benefit and cost. Authors' reply (2008) (0)
[Basic and clinical aspects of calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics]. (2008) (0)
[PTH assay: new and future]. (2001) (0)
[Countermeasure for patients with bone disease due to hemodialysis]. (1995) (0)
681-P: Survey of Medical Staff on Use of Glucagon Injection in the Event of Serious Hypoglycemia in Japanese Diabetic Patients—Reason for Poor Spread of Glucagon Use in Japan (2019) (0)
Renal osteodystrophy and secondary hyperparathyroidism. (2002) (0)
Dialysis: Is the road to survival paved with good mineral management? (2011) (0)
[Whole-PTH assay--new method for assessment of parathyroid function]. (2004) (0)
Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients (2021) (0)
[Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis]. (2005) (0)
Laparoscopic nephroureterectomy, total cystectomy, and urethrectomy due to bilateral asynchronous renal pelvic and ureteral tumor followed by initiation of hemodialysis-a case report (2004) (0)
SP640CALCIMIMETICS AND VITAMIN D ANALOGUES INDUCE APOPTOSIS IN CULTURED PARATHYROID PSEUDOGLANDS (2015) (0)
CKD / Mineral bone disease (2011) (0)
A case of dermatomyositis assciated with toxoplasmosis. (1986) (0)
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 8. CKD-MBD]. (2012) (0)
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties (2022) (0)
Renal osteodystrophy and vitamin D derivatives: cellular mechanisms of hyperparathyroidism in uremia. (1992) (0)
Phosphorylation of β1-integrin in juxtaglomerular cells helps control blood pressure during the progression of diabetic nephropathy (2021) (0)
Guideline 2000 for Selective Percutaneous Ethanol Injection Therapy (PEIT) of Parathyroid in Chronic Dialysis Patients (2000) (0)
MP674LOWER TRACP-5B DUE TO CALCIUM OVERLOAD IS ASSOCIATED WITH HIGHER MORTALITY IN MAINTENANCE HEMODIALYSIS PATIENTS (2017) (0)
SaO028FGF23 MITIGATES HYPERPHOSPHATEMIA AND CAUSES LOW 1,25-DIHYDROXYVITAMIN D LEVELS AFTER ACUTE KIDNEY INJURY IN RATS (2018) (0)
[Vitamin D metabolism in chronic kidney failure]. (1992) (0)
Contents Vol. 32, 2011 (2011) (0)
[Present status and problems in vitamin D and sevelamer therapy (discussion)]. (2005) (0)
[A case of dermatomyositis associated with toxoplasmosis]. (1986) (0)
In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’” (2022) (0)
The roles of Vitamin D in Secondary Hyperparathy-roidism (2004) (0)
The Role Of C-Type Natriuretic Peptide ( CNP ) In Mouse Fracture Healing (2013) (0)
Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients (2022) (0)
1, 25-Dihydroxyvitamin D3 receptor density is decreased in an advanced type of parathyroid hyperplasia due to chronic renal failure (1994) (0)
Kobe University Repository : Kernel タイトル Tit le A Possible Role of Thioredoxin Interact ing Protein in the Pathogenesis of Streptozotocin-induced Diabet ic Nephropathy 著者 (2018) (0)
SP603Understanding the impact on mortality of long term serum phosphorus control using a 6 month area under the curve approach in the International Dialysis Outcomes and Practice Patterns Study (DOPPS) (2019) (0)
Acute cardiac overload does not induce cardiac or skeletal expression of fibroblast growth factor 23 in rats (2021) (0)
Cost-Effectiveness Analysis of Alendronate Therapy for Secondary Prevention of Osteoporotic Fractures (2013) (0)
WITHDRAWN: Suppression of ABCG2 expression by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism (2015) (0)
OJ-260 The effect of oral charcoal adsorbent (AST-120) on the progression of cardiac abnormalitites in chronic kidney disease(OJ44,Kidney/Renal Circulation/CKD 2 (H),Oral Presentation (Japanese),The 73rd Annual Scientific Meeting of The Japanese Circulation Society) (2009) (0)
FP596EFFICACY AND SAFETY OF ETELCALCETIDE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM INADEQUATELY CONTROLLED WITH CINACALCET (2018) (0)
Neuropharmacological Study on the Mechanism for the Development of Pain (1971) (0)
Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients (2019) (0)
List of Contributors (2009) (0)
PMS71 Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women in Japan (2012) (0)
[Targeted therapy for mineral and bone disorder]. (2016) (0)
Importance of the Evaluation of Renal Function for the Prevention of Hypoglycemia in Elderly Diabetes Patients. (2020) (0)
Decline in functional status and mortality in patients on hemodialysis: Results from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS) (2019) (0)
[Pathophysiological study on water electrolyte imbalance--special reference to calcium-phosphorus metabolism disorders]. (2003) (0)
937 EFFICACY OF A DIRECT RENIN INHIBITOR COMBINED WITH ANGIOTENSIN II RECEPTOR BLOCKERS FOR HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2012) (0)
The Authors Reply. (2015) (0)
CKD-MBD as a systemic disorder. (2009) (0)
[Contribution of Japanese researchers to progress in studies on nephrology in the last 100 years: Molecular mechanism of calcium and vitamin D metabolism in the kidneys]. (2002) (0)
Bone and mineral diseases - 2 (2012) (0)
[Calcium and vitamin D metabolism in the kidney-parathyroid system]. (2003) (0)
SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS (2020) (0)
Bone disease - 1 (2009) (0)
Effect of PTH on the Hematologic System (2020) (0)
[Programs for continuing medical education: B session; 7. Water and electrolyte disorders]. (2012) (0)
[Short-term treatment of a VIPoma with somatostatin analogue in advance of curative operation]. (1988) (0)
Correction to: Preventive effect of early introduction of everolimus and reduced‑exposure tacrolimus on renal interstitial fibrosis in de novo living‑donor renal transplant recipients (2019) (0)
Contents Vol. 28, 2008 (2008) (0)
SP366DISRUPTED TUBULAR PTH/PTH1R SIGNALING IS A POSSIBLE CANDIDATE FOR POSTSURGICAL KIDNEY INJURY IN PATIENTS WITH ADVANCED HYPERPARATHYROIDISM (2017) (0)
S68 Effect of calcimimetic R-568 in apolipoprotein E deficient mice with surgically induced kidney disease (2009) (0)
Association of Hyperkalemia and Hypokalemia with Patient Characteristics and Clinical Outcomes in Japanese Hemodialysis (HD) Patients (2023) (0)
Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis. (2022) (0)
Adrenal Cushingʼs syndrome: preoperative diagnosis and postoperative treatment (2015) (0)
Dialytic therapy. II. A countermeasure of a dialysis complication. 2. Dialysis osteopathia. (1995) (0)
SP363RELATIONSHIP BETWEEN SERUM SCLEROSTIN, BONE METABOLISM MARKERS, AND FRACTURE IN HEMODIALYSIS PATIENTS: TOKAI DIALYSIS COHORT STUDY (2017) (0)
[Skeletal complications of renal insufficiency]. (2004) (0)
5. Mineral Metabolism in Chronic Kidney Disease (2016) (0)
Taste Disorder As A Common Cause Of Enhanced Salt Intake In Dialysis Patients (2012) (0)
Heart and bone in CKD - B (2013) (0)
Parathyroid disorder and calcium metabolism abnormality. II. Disease state and treatments. 2. Hypocalcemia disease. 3) Renal osteodystrophy and secondary hyperparathyroidism. (1999) (0)
Contents Vol. 26, 2006 (2007) (0)
Results of a survey on practice patterns at the end of a study involving CKD-MBD management at dialysis facilities: : As a part of MBD-5D study@@@―透析MBDアウトカム研究より― (2013) (0)
[Management of phosphate in nutrition therapy for chronic kidney disease]. (2009) (0)
498-P: Involvement of Phosphorylation of Beta-1 Integrin in Renin Production and Blood Pressure Regulation in Diabetic Nephropathy (2019) (0)
[Kidney and bone update : the 5-year history and future of CKD-MBD. The changes after the introduction of CKD-MBD as a new entity]. (2012) (0)
Subject Index Vol. 30, 2009 (2009) (0)
Acute Kidney Injury (AKI) and Chronic Renal Failure. (2010) (0)
FO028COMPREHENSIVE THREE-DIMENSIONAL ANALYSIS (CUBIC-KIDNEY) REVEALS ABNORMAL RENAL SYMPATHETIC NERVES AFTER ISCHEMIA-REPERFUSION INJURY (2019) (0)
MP354NO CLEAR ASSOCIATION WAS FOUND BETWEEN HIGH FRACTURE RISK AND MINERAL METABOLIC MARKERS AMONG JAPANESE DIALYSIS PATIENTS (2016) (0)
A case of subclinical primary aldosteronism and subclinical Cushing's syndrome without risk factors of cardiovascular disease (2016) (0)
FGF23 and Klotho in Chronic Kidney Disease (2020) (0)
Recent Advances in CKD‐MBD Research (2011) (0)
Contents Vol. 30, 2009 (2009) (0)
A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein (2020) (0)
SAT-245 CARDIOVASCULAR DISEASE HISTORY AND BETA-BLOCKER PRESCRIPTION PATTERNS FOR JAPANESE AND AMERICAN CKD PATIENTS: COLLABORATION BETWEEN CRIC AND CKD-JAC (2019) (0)
[Secondary hyperparathyroidism]. (2005) (0)
Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia (2008) (0)
[A case of insulinoma with the splenic hamartoma presenting a vascular blush in arteriography]. (1989) (0)
[113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Mineral Metabolism in Chronic Kidney Disease]. (2016) (0)
Consultants for the American Journal of Nephrology 2006 (2007) (0)
Bone disease in CKD 5D (2011) (0)
Comparison of intravenous maxacalcitol therapy and oral calcitriol pulse therapy following percutaneous ethanol injection therapy (PEIT) for secondary to hyperparathyroidism (2006) (0)
FP411VITAMIN D RECEPTOR ACTIVATOR MAXACALCITOL PREVENTS THE PROGRESSION OF DIABETIC CARDIOMYOPATHY INDEPENDENTLY OF RENIN ANGIOTENSIN SYSTEM INHIBITION (2015) (0)
Not only for the risk of bone fracture (2015) (0)
PTH Regulation by the Klotho/FGF23 Axis in CKD (2020) (0)
Why and how high should parathyroid hormone level be controlled in CKD patients ? (2013) (0)
CHRONIC KIDNEY DISEASE. BONE DISEASE (2015) (0)
Phosphate as another major regulator of parathyroid function. (2000) (0)
Contents Vol. 118, 2011 (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Masafumi Fukagawa?

Masafumi Fukagawa is affiliated with the following schools:

Masafumi Fukagawa's Academic­Influence.com Rankings

Masafumi Fukagawa's Degrees

Similar Degrees You Can Earn

Why Is Masafumi Fukagawa Influential?

Masafumi Fukagawa's Published Works

Published Works

What Schools Are Affiliated With Masafumi Fukagawa?

Masafumi Fukagawa's AcademicInfluence.com Rankings